PD L1 News and Research

RSS

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Removing copper from blood can destroy deadliest cancers that are resistant to immunotherapy

Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.

19 Aug 2020

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Scientists introduce a new approach for immunological tumor treatment

Our immune system ought to be able to recognize and kill tumor cells. However, many tumors deceive the immune system.

8 Jul 2020

Scientists engineer natural killer cells that target tumors and their immunosuppressive allies

Scientists have engineered natural killer immune cells that not only kill head and neck tumor cells in mice but also reduce the immune-suppressing myeloid cells that allow tumors to evade the immune response, according to a new study in eLife.

7 Jul 2020

Protein profile in serum reflects COVID-19 severity

The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.

25 Jun 2020

Manipulating macrophages could be a viable strategy for treating cancer

Most traditional cancer therapies target either the tumor cells themselves or indiscriminately kill any rapidly dividing cell.

22 Jun 2020

New combination of biomarkers can benefit patients with advanced bladder cancer

In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.

18 Jun 2020

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

11 Jun 2020

Jane and Aatos Erkko Foundation awards 1.5 million euros to support breast cancer study

1.5 million euros funding supports a new investigator-initiated breast cancer clinical trial in Finland that takes on MYC.

11 Jun 2020

Novel immunotherapy targeting myeloid immune cells reduces tumor growth

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions.

27 May 2020

Novel biomarkers linked to improved outcomes with immunotherapy in metastatic breast cancer

Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

22 May 2020

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.

20 May 2020

Roswell Park team proposes possible new strategy for treating pancreatic cancer

A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology.

18 May 2020

Innovative approach turns 'cold' tumors 'hot' to improve cancer immunotherapy

Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns “cold” tumors “hot”. “Cold”, immune-desert tumors are classically immunotherapy-resistant.

13 May 2020

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery.

27 Apr 2020

Combination therapy boosts the immune system's appetite for cancer

A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests.

24 Apr 2020

Researchers uncover how cancer cells don their invisibility cloaks

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood.

22 Apr 2020

Tumors commandeer cell death pathway to avoid immune system attack after radiation

Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response, a new study led by UTSW scientists suggests.

13 Apr 2020